Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in
 heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching
 target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration
 regimens.
Inclusion Criteria:

 -  Age ≥ 18 years; CHF with New York Heart Association class II-IV; left ventricular
 ejection fraction ≤ 35%; on beta blockers

 Exclusion Criteria:

 -  Potassium > 5.2 mmol/l; estimated glomerular filtration rate < 30 ml/min/1.73 m2;
 systolic blood pressure <100 mmHg or > 180 mmHg; history of intolerance to recommended
 target doses of angiotensin converting enzyme inhibitors or angiotensin receptor
 blockers

 Other protocol-defined inclusion/exclusion criteria may apply.